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Celiac disease is a permanent intolerance to the gliadin fraction of wheat gluten and to similar barley and rye proteins that occurs
in genetically susceptible subjects. After ingestion, degraded gluten proteins reach the small intestine and trigger an inappropriate
T cell-mediated immune response, which can result in intestinal mucosal inﬂammation and extraintestinal manifestations. To
date, no pharmacological treatment is available to gluten-intolerant patients, and a strict, life-long gluten-free diet is the only
safe and eﬃcient treatment available. Inevitably, this may produce considerable psychological, emotional, and economic stress.
Therefore, the scientiﬁc community is very interested in establishing alternative or adjunctive treatments. Attractive and novel
forms of therapy include strategies to eliminate detrimental gluten peptides from the celiac diet so that the immunogenic eﬀect
of the gluten epitopes can be neutralized, as well as strategies to block the gluten-induced inﬂammatory response. In the present
paper, we review recent developments in the use of enzymes as additives or as processing aids in the food biotechnology industry
to detoxify gluten.
1.CeliacDisease
Celiac Disease (CD) is a condition aﬀecting 1:70–1:200
individuals worldwide that may be diagnosed at any age
[1, 2]. In a population-based study, increasing prevalence
andhighincidenceofCD(1:47)inelderlypeople(olderthan
5 2y e a r so fa g e )h a v eb e e nr e m a r k e d[ 3]. CD is a permanent
food intolerance to the ingested gliadin fraction of wheat
gluten and similar alcohol-soluble proteins of barley and
rye in genetically susceptible subjects [4, 5]. Most patients
tolerate oats without any signs of intestinal inﬂammation
probably because oat avenins are phylogenetically more
distant from the analogous proteins in wheat, rye, and
barley [6]. Nonetheless, a few individuals with clinical oat
intolerance have avenin-reactive mucosal T cells that can
cause mucosal inﬂammation [7]. In children prone to CD,
exposure to wheat, barley, and rye in the ﬁrst three months
of life signiﬁcantly increases the risk of developing CD
compared with exposure between 4 and 6 months [8]
whereas breastfeeding exerts a protective eﬀect and the risk
of CD is reduced if children are still being breast-fed when
dietary gluten is introduced [9].
The clinical features of CD vary considerably [2]. Intesti-
nal symptoms are frequent in children diagnosed within
the ﬁrst two years of life. However, asymptomatic patients
can be found: failure to thrive, chronic diarrhoea, vomiting,
abdominal distension, muscle wasting, anorexia, and general
irritability are present in most cases. The wider use of
serological screening tests is making it easier to recognize
extra-intestinalmanifestationssuchasshortstature,anaemia
unresponsive to iron therapy, osteoporosis, ataxia, periph-
eral neuropathies, hypertransaminasemia, and unexplained
infertility [10]. It is also noteworthy that CD is associated
with a high prevalence of concomitant autoimmune diseases
(approximately 5–10 times greater than in the general pop-
ulation), such as endocrine autoimmune diseases, thyroid
d i s e a s e s ,a n ds e l e c t i v eI g Ad e ﬁ c i e n c y ,a sw e l la so fg e n e t i c
disorders, such as Down and Turner’s syndromes [11].2 Enzyme Research
Because symptoms may improve with a gluten-free diet,
it is thought that gluten plays a key role in the pathogenesis
of this disease.
2. Gluten
The grain protein content of wheat varies between 8 and 17
percent, depending on genetic make-up and external factors
associated with the crop. A unique property of wheat ﬂour
is that, when in contact with water, the insoluble protein
fraction forms a viscoelastic protein mass known as gluten.
Gluten,whichcomprisesroughly78to85percentofthetotal
wheat endosperm protein, is a very large complex mainly
composed of polymeric (multiple polypeptide chains linked
by disulphide (SS) bonds) and monomeric (single chain
polypeptides) proteins known as glutenins and gliadins,
respectively. Gliadin consists of proteins containing α/β-, γ-,
and ω-gliadins. In contrast to α/β-a n dγ-gliadins, which
form three and four intramolecular (SS) bonds, respectively,
ω-gliadinslackcysteineresidues.Gluteninisaheterogeneous
mixture of SS-linked polymers with a largely unknown
polymer structure. A glutenin polymer consists of glutenin
subunits of high or low molecular weight that are connected
byintermolecularSSbonds.Gluteninsconferelasticity,while
gliadins mainly confer viscous ﬂow and extensibility to the
gluten complex. Thus, gluten is responsible for most of the
viscoelastic properties of wheat ﬂour doughs, and it is the
main factor dictating the use of a wheat variety in bread and
pasta making. Gluten viscoelasticity, for end-use purposes, is
commonly known as ﬂour or dough strength [12, 13].
Gliadins and glutenins have a unique amino acid com-
position with a high content of proline (15%), hydrophobic
amino acids (19%), and glutamine (35%), hence they are
named prolamins. Moreover, they contain domains with
numerous repetitive sequences rich in those amino acids.
Because of this glutamine- and proline-rich structure, gluten
proteinsareresistanttocompletedigestionbypancreaticand
brush border proteases [14, 15].
3. PosttranslationalModiﬁcationof Glutenby
TissueTransglutaminase
CD is triggered by an inappropriate T cell-mediated immune
response to dietary gluten proteins. Consequently, CD
patients display various degrees of intestinal inﬂammation,
ranging from mild intraepithelial lymphocytosis to severe
subepithelial mononuclear cell inﬁltration that results in
total villous atrophy coupled with crypt hyperplasia. The
most evident expression of autoimmunity in CD is the
presence of serum antibodies to tissue transglutaminase
(tTG), the main autoantigen of endomysial antibodies [16].
tTG is a member of a Ca2+-dependent enzyme family
involved in post-translational modiﬁcations of proteins.
tTG prevalently catalyzes the formation of stable isopeptide
bonds between the γ-carboxamide group of the protein-
bound glutamine residue and an appropriate amino group,
either the ε-amino group of a protein-bound lysine residue
or a small biogenic amine molecule such as putrescine,
spermine, spermidine, and histamine. However, the absence
of suitable nucleophilic amines and a low pH favours tTG
deamidation of protein-bound glutamine residues [17].
The presence of tTG-speciﬁc autoantibodies only in
patients who have gluten in their diet suggests that the
generation of such antibodies in CD requires gluten as
an exogenous trigger. The proposed mechanism by which
autoimmunity develops in CD is that the enzyme tTG gen-
erates additional antigenic epitopes by cross-linking gliadin
peptides to itself and/or to other protein substrates, and this
stimulates mucosal T cells to produce autoantibodies against
tTG and gliadin [18]( Figure 1). Since the existence of tTG-
speciﬁc T cells in the intestinal mucosa of untreated patients
is not proven, it is hypothesized that the production of anti-
tTG antibodies is driven completely by intestinal gliadin-
speciﬁc T cells. The observation that anti-tTG antibody
titers fall and can become undetectable during a gluten-
free diet suggests that B cell activity depends on persistent
antigen presentation. In a pioneering study in 1990, Porta
et al. demonstrated that wheat glutelins and gliadins, as
well as puriﬁed A-gliadin, act as acyl donor substrates for
tTG [19]. In particular, by performing incubations in vitro
both in the presence of radiolabeled polyamines and in their
absence, Porta et al. showed that these proteins were able
to produce not only γ(glutamyl)polyamine adducts but also
polymeric complexes, probably through intermolecular ε(γ-
glutamyl)lysine crosslinks. In the case of A-gliadin, the single
lysil residue occurring in the amino acid sequence (K-186)
is assumed to act as an acyl acceptor site. It is worth noting
that the increase of both tTG activity in situ and tTG protein
has been detected at critical sites of celiac mucosae, such as
the intestinal brush border and subepithelial compartments
[20].
The involvement of tTG in the pathogenesis of CD
could be also due to another distinct but interdependent
pathway via a gliadin-derived peptide deamidation reaction
(Figure 1). Gluten peptides are speciﬁcally recognized by
human leukocyte antigen (HLA)-DQ2/DQ8, a class II major
histocompatibility complex [21] .I n d e e d ,C Di ss t r o n g l y
associated with the genes encoding HLA-DQ2, and gluten-
speciﬁcCD4+ intestinalTcellscanbeisolatedfromintestinal
biopsies of CD patients but not from healthy controls [21].
By contrast, there is no evidence of T cell-mediated reactivity
against dietary gliadin in the nonceliac mucosa. Moreover,
gliadin-speciﬁc T lymphocytes from CD intestinal mucosa
are mainly of the Th1/Th0 phenotype, which after gliadin
recognition, release prevalently proinﬂammatory cytokines
dominated by interferon (IFN)-γ [22] and interleukin (IL)-
10[23].IthasbeenhypothesizedthattTGmightberesponsi-
ble for the deamidation of speciﬁc glutamine residues within
naturally digested gluten peptides, especially at low pH.
Such tTG-catalyzed posttranslational modiﬁcation generates
negatively charged amino acid residues that bind with an
increased aﬃnity to the HLA-DQ2 or HLA-DQ8 molecules,
thus potentiating T cell activation [24, 25]. Recognition of
theTcellepitopehasbeenparticularlydiﬃcultsincegliadin’s
peculiar amino acid composition and its high glutamine
content make it an excellent tTG substrate. A 33mer peptide,
containing three of the most immunogenic epitopes, wasEnzyme Research 3
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Figure 1:Tissuetransglutaminase(tTG)-mediatedpost-translationalmodiﬁcationsinceliacdisease.Gliadinpeptidesreachthesubepithelial
region of the intestinal mucosa. Here, tTG deamidation of speciﬁc glutamines of gliadin peptides generates potent immunostimulatory
epitopes that are presented via HLA-DQ2/DQ8 on antigen-presenting cells (APC) to CD4+ T cells. Activated gliadin-speciﬁc CD4+ Tc e l l s
produce high levels of pro-inﬂammatory cytokines, thus inducing a Th1 response that results in mucosal remodelling and villous atrophy.
In addition, tTG transamidation activity generates tTG-gliadin complexes that bind to tTG-speciﬁc B cells, are endocytosed and processed.
Gliadin-DQ2/DQ8 complexes are then presented by the tTG-speciﬁc B cells to gliadin-speciﬁc T cells, a process that leads to the production
of anti-tTG antibodies.
identiﬁedasoneofthemainstimulatorsoftheinﬂammatory
response to gluten, resistant to intestinal proteases [26, 27].
However, Camarca et al. recently demonstrated that the
repertoire of gluten peptides recognized by adult celiac
patients is larger than had been previously thought, and it
diﬀers from one individual to another. Indeed, they found
several active gluten peptides with a large heterogeneity of
responses [28].
Although the role of gluten in activating gluten-speciﬁc
T lymphocytes in the lamina propria is well established, it
hasbeendemonstratedthatglutencontainspeptidesthatcan
stimulate cells of the innate immune system. The prototype
of innate peptides is peptide 31–43/49, which has been
shown to be toxic for CD patients both in vitro and in vivo
[29, 30]. Peptide 31–43/49 can reorganize intracellular actin
ﬁlaments [31], induce maturation of bone-marrow-derived
dendriticcells[32],and,byaﬀectingepithelialgrowthfactor-
receptor decay, induce epithelial cell proliferation [33].
The peptide also stimulates the synthesis and release of
the proinﬂammatory cytokine IL-15 that can promote an
adaptive immune response [34] involving CD4+ T cells that
recognize various deamidated gliadin peptides [25]. Most of
theeventsrelatedtoinnateimmuneactivationwereinhibited
by antibodies neutralizing IL-15, thus conﬁrming that this
cytokine mediates intestinal mucosal damage induced by
ingestion of gliadin. In particular, Barone et al. investigated
the molecular mechanisms of the gliadin-induced IL15
increase and discovered that gliadin peptide 31–43 increases
thelevelsofIL-15onthecellsurfaceofCaCo-2cellsprobably
by interfering with its intracellular traﬃcking [35].4 Enzyme Research
4.Treatment of CeliacDisease
To date, no pharmacological treatment is available to gluten-
intolerant patients. A strict, life-long, gluten-free diet is
the only safe and eﬃcient treatment available, although
it results in a social burden. Adhering to a gluten-free
diet can have a signiﬁcant negative impact on perceived
quality of life and may produce considerable psychological,
emotional, and economic stress. Moreover, this requirement
for dietary compliance is made more diﬃcult by the
exclusion of wheat, rye, and barley from the diet, which
are important sources of iron, dietary ﬁbre, and vitamin B,
especially for adolescents and adults who need continuous
monitoring by dieticians [36]. A lifelong gluten-free diet
can be extremely diﬃcult since gluten may be present
i nn o n s t a r c h yf o o d ss u c ha ss o ys a u c ea n db e e r ,a sw e l l
as in nonfood items including some medications, postage
stamp glue, and cosmetics (e.g., lipstick). CD patients can,
therefore,beexposedinadvertentlytogluten.Moreover,even
after many years of gluten avoidance, CD patients never
acquire tolerance to gliadin, and re-exposure to the antigen
reactivates the disease. Finally, it is worth noting that a small
groupofpatientswithCD(2%–5%)failtoimproveclinically
and histologically upon elimination of dietary gluten. This
complication is referred to as refractory CD, and it imposes
a serious risk for developing lethal enteropathy-associated T-
cell lymphoma.
In 2000, the Codex Alimentarius Commission of the
World Health Organization and the FAO described gluten-
free foods consisting of, or made only from, ingredients
which do not contain any prolamines from wheat or any
Triticum species, such as spelt, kamut or durum wheat, rye,
barley,oats,ortheircrossbredvarietieswithaglutenlevelnot
exceeding 20ppm [37, 38]. At present, gluten-free products
are not widely available; they are usually expensive, and they
have poor sensory and shelf life properties. Research and
development are currently focused on improving mouth-
feel, ﬂavour, and rheology of gluten-free products. Gluten is
responsible for most of the viscoelastic properties of wheat
ﬂour doughs, and its absence can result in a baked bread
with a crumbling texture, poor colour and other postbaking
quality defects [37]. For all these reasons the search for
safe and eﬀective therapeutic alternatives to a gluten-free
diet, which are compatible with a normal social lifestyle,
is of great importance. Advances in our understanding
of the complex mechanisms involved in CD pathogenesis
have opened several promising avenues for therapeutic
intervention aimed at targeting each factor involved in the
disease onset, some of which are being tested in early clinical
trials [39]. The identiﬁcation of T-cell stimulatory gliadin
sequences (33mer peptide) is important so that peptide
analoguesof gliadin epitope(s) canbe engineered to generate
peptides that exert antagonistic eﬀects. Of course, the
chances of success of using peptide analogues to modulate
speciﬁc immune responses could be hampered by the wide
heterogeneity of the gliadin T-cell epitopes. Elucidation of
the hierarchy of pathogenic gliadin epitopes and their core
region is required before a peptide-based therapy can be
designed [40]. Antibodies to IL-15 have also been proposed
as a treatment strategy, particularly in cases of refractory
sprue because of intraepithelial lymphocyte activation in
this condition [41], as well as antibodies to IFN-γ [42].
Otherpromisingtreatmentstrategiesareaimedatpreventing
gliadin presentation to T cells by blocking HLA-binding sites
and using IL-10 as a tool for promoting tolerance [23]. To
reverse the toxic eﬀects induced by gliadin in human intesti-
nal cells and gliadin-sensitive HCD4-DQ8 mice, Pinier et al.
proposed a completely diﬀerent strategy based on the use of
synthetic sequestering polymeric binders that can complex
and neutralize gliadin in situ. Coadministration of synthetic
polymeric binders and gliadin to HLA-HCD4/DQ8 mice
attenuated gliadin-induced changes in the intestinal barrier
and reduced intraepithelial lymphocyte and macrophage cell
counts [43]. Recent new therapeutic approaches include
correctionoftheintestinalbarrierdefectagainstglutenentry.
An intestinal permeability blocker (AT1001), which is an
inhibitor of the zonulin pathway that acts to prevent gliadin
from inducing increased intestinal permeability, is currently
in a phase IIb clinical study [44]. Finally, a vaccine that could
desensitize or induce tolerance in individuals with CD has
been proposed [45, 46].
Besides therapeutic treatments, transgenic technology
and breeding ancient varieties have been tried with the goal
of developing grains that have a low or zero content of
immunotoxic sequences, but with reasonable baking quality.
However, these approaches are diﬃcult due to the number
and the repetition of sequence homologies in the cereal
protein family, and because cereals like wheat are hexaploid
[47, 48].
5. Enzyme Therapy
Enzyme supplement therapies are focused on inactivating
immunogenic gluten epitopes (Table 1).
5.1. Oral Administration of Bacterial Endopeptidases. After
ingestion, degraded gluten proteins reach the small intestine.
However, because of their unusually high proline and
glutamine content, especially in immunodominant gliadin
peptides like the 33mer, gluten is poorly degraded by the
enzymes present in the gastrointestinal tract. Hence, oral
enzyme therapy has been suggested as an alternative to the
gluten-free diet. Promising enzymes (expressed in various
microorganisms) tested are the prolyl oligopeptidases from
Flavobacterium meningosepticum, Sphingomonas capsulate,
and Myxococcus xanthus. These enzymes are capable of
degrading proline-containing peptides that are otherwise
resistant to degradation by proteases in the gastrointestinal
tract in vitro [49–51]. However, most of these enzymes are
irreversibly inactivated in the stomach by pepsin and acidic
pH, thus failing to degrade gluten before it reaches the small
intestine [49]. Encapsulation of these prolyl oligopeptidases
was proposed in order to protect them from gastric juices
[51]. However, in a recent ex vivo study, using biopsy-
derived intestinal tissue mounted in Ussing chambers, it was
observed that only high doses of prolyl oligopeptidase were
capable of eliminating the accumulation of immunogenicEnzyme Research 5
peptidesintheserosalcompartment[50].Thisindicatesthat,
even if the enzyme were encapsulated, it is too ineﬃcient
to degrade gluten before it reaches the proximal part of
the duodenum, the site where gluten triggers inﬂammatory
T-cell responses [50]. Mitea et al. recently investigated a
new prolyl endoprotease from Aspergillus niger. This enzyme
was found to degrade gluten peptides and intact gluten
proteins eﬃciently in the stomach, to such an extent that
hardly any traces of gluten reached the duodenal com-
partment [52]. Moreover, the optimum pH of this enzyme
is compatible with that found in the stomach and the
enzyme is resistant to degradation by pepsin. Finally, prolyl
endoprotease from Aspergillus niger is derived from the food
grade microorganism and is available on an industrial scale.
These results indicate that this enzyme might be suitable
for oral supplementation to degrade gluten proteins in food
before they reach the small intestine [52]. Recently, Gass
et al. evaluated a new combination therapy, consisting of
two gastrically active enzymes that detoxify gluten before its
release in the small intestine. They used a glutamine-speciﬁc
endoprotease (EP-B2; a cysteine endoprotease from ger-
minating barley seeds) and a prolyl-speciﬁc endopeptidase
from Sphingomonas capsulata, for its ability to digest gluten
under gastric conditions. Endoprotease EP-B2 extensively
hydrolyzes the gluten network in bread into relatively
short (but still inﬂammatory) oligopeptides, whereas prolyl-
speciﬁc endopeptidase from Sphingomonas capsulata rapidly
detoxiﬁes oligopeptides after primary proteolysis at internal
proline residue level to yield nontoxic metabolites [53].
A practical advantage of this combination product is that
both enzymes are active and stable in the stomach and can
therefore be administered as lyophilized powders or simple
capsules or tablets.
5.2. Pretreatment of Whole Gluten with Bacterial-Derived
Peptidase. An alternative approach to detoxify gluten is
represented by the digestion of wheat gluten peptides
with bacterial-derived peptidase during food processing and
before administration to patients. Traditional methods to
prepare cereal foods, including long fermentation times by
selected sourdough lactic acid bacteria, have mostly been
substituted by the indiscriminate use of chemical and/or
baker’s yeast leavening agents. Under these circumstances,
cereal components (e.g., proteins) are subjected to very
mild or absent degradation during manufacture, resulting,
probably, in reduced digestibility compared to traditional
and ancient sourdough baked goods [54]. Di Cagno et al.
selected four sourdough lactobacilli (L. alimentarius 15M,
L. brevis 14G, L. sanfranciscensis 7A, and L. hilgardii 51B)
that showed considerable hydrolysis of albumin, globulin,
and gliadin fractions during wheat sourdough fermentation.
These lactobacilli had the capacity to hydrolyze the 31–
43 fragment of A-gliadin in vitro and, after hydrolysis,
greatly reduced the agglutination of K 562(S) subclone
cells of human myelogenous leukemia origin by a toxic
peptic-tryptic digest of gliadins [55]. On the basis of these
results, and with the goal of decreasing gluten intolerance
in humans, the authors investigated a novel bread making
method that used selected lactobacilli to hydrolyze various
Pro-rich peptides, including the 33mer peptide, for the
production of sourdoughs made from a mixture of wheat
and nontoxic oat, buckwheat, and millet ﬂours [56]. After
24hoursoffermentation,wheatgliadinsandlow-molecular-
mass, alcohol-soluble polypeptides were almost completely
hydrolyzed. Proteins extracted from sourdough were used
for in vitro agglutination tests on K 562(S) subclone cells of
human origin and to produce two types of bread, containing
ca. 2g of gluten. The latter were used in an in vivo double-
blind acute challenge of CD patients. Agglutination testing
of K 562(S) cells and the acute in vivo challenge showed
improved tolerance of breads containing 30% wheat ﬂour
[56]. The reported data suggest that long-time fermentation
in the presence of a mixture of selected lactic acid bacteria
seemed to be indispensable to reduce toxicity. In actual fact,
diﬀerent probiotic bacterial strains have their characteristic
set of peptidases, which may diverge considerably from
each other and have variable substrate speciﬁcities. In
line with this concept, diﬀerent probiotic bacterial strains
have been tested. Among probiotic preparations, VSL#3,
a highly concentrated mixture of lactic acid and biﬁdo-
bacteria, was able to hydrolyze completely the α2-gliadin-
derived epitopes 62–75 and 33mer (750ppm) [57]. It is
interesting to underline that probiotics, deﬁned as the
viable microorganisms that exhibit a beneﬁcial eﬀect on
the health of the host by improving its intestinal microbial
balance, could directly modulate the function of epithelial
cells. It has been reported that diﬀerent probiotic strains,
including the VSL3# preparation, increase epithelial barrier
function by stabilizing tight junctions and inducing mucin
secretion in epithelial cells [57, 58]. Furthermore, several
probiotic bacterial strains are able to protect the epithe-
lium, presumably by the aforementioned mechanisms, from
various insults, including pathogenic bacteria [59, 60]a n d
inﬂammatory cytokines [61, 62]. More recently, Rizzello et
al. showed that fermentation with a complex formula of
sourdough lactobacilli decreased the concentration of gluten
to below 10ppm [63]. Speciﬁcally, they used a mix of ten
sourdough lactobacilli that were selected for their peptidase
systems capability to hydrolyze Pro-rich peptides, including
the 33mer peptide, together with fungal proteases, that are
routinely used as improvers in the baking industry. In this
way, wheat and rye breads or pasta, if supplemented with
gluten-free ﬂour-based structuring agents, may be tolerated
by CD patients. Agglutination testing of K 562(S) cells and
an acute in vivo challenge showed improved tolerance of
breads containing 30% wheat ﬂour. Moreover, prolonged
in vivo challenge of CD patients conﬁrms reduced toxicity
of gluten fermented with selected lactobacilli and fungal
proteases. In fact, CD patients (age >12 years old) on
a gluten-free diet for at least ﬁve years were challenged
with a daily intake of 10g of hydrolysed gluten (<20ppm
of gluten) for 2 months. Intestinal functional tests, as
well as CD serum antibodies (anti-tTG, anti-endomysium),
and duodenal histology and immunohistochemistry at
the beginning and after 60 days of challenge showed
that all parameters were normal, i.e., no villous atrophy)
[64].6 Enzyme Research
Table 1: Potential enzyme therapies for celiac disease.
Target for
detoxiﬁcation Detoxifying agent Mechanism of action Status of
research
Ingested gliadin
peptides
Prolyl endopeptidases from:
Hydrolysis of
proline-rich peptides of
gliadin
Preclinical S. capsulate [49]
F. meningosepticum [50]
M. xanthus [51]
Prolyl endopeptidases from: A. niger [52] Clinical trial
Prolyl endopeptidases from: S. capsulate in
combination with a glutamine-speciﬁc
endoprotease (EP)-B2 from germinating barley
[53]
Clinical trial
Flour Sourdough lactobacilli-derived peptidases [56] Hydrolysis of
proline-rich peptides of
gliadin
Clinical trial
Sourdough lactobacilli-derived peptidases in
combination with fungal proteases [64] Clinical trial
Flour Transglutaminase enzymes [67]
Transamidation of
gliadin peptides with
lysine methyl ester
Preclinical
Mucosal tTG Irreversible thiol-reactive reagents, competitive
peptidic, and nonpeptidic substrates [69]
unspeciﬁc or speciﬁc
tTG inhibition Preclinical
The use of proteases from germinating wheat seeds has
also been proposed to create safe cereal products for CD
patients [65, 66].
5.3. Transamidation of Gliadin. tTG-catalyzed deamidation
of speciﬁc glutamine residues within naturally digested
gluten peptides generates negatively charged amino acid
residues that bind with an increased aﬃnity to the HLA-
DQ2/DQ8 molecules, thus potentiating T cell activation.
Based on this assumption, Gianfrani et al. proposed an
enzyme strategy to inactivate immunogenic peptide epitopes
and, at the same time, to preserve the integrity of the
protein structure via the transamidation of wheat ﬂour
with a food-grade enzyme and an appropriate amine donor
[67]. Interestingly, a recent study showed that the formation
of the DQ2-α-II epitope was blocked by 5-biotinamido
pentylamine and by monodansylcadaverine, reagents known
tocross-linkglutamineresidues[68].Tothisend,theauthors
treated wheat ﬂour with tTG and lysine methyl ester; the
lysine-modiﬁed gliadin peptides lost almost completely their
aﬃnity to bind to HLA-DQ2. Moreover, lysine-modiﬁed
gliadinpeptidescausedadrasticreductioningliadin-speciﬁc
IFN-γ production in intestinal T-cell lines derived from CD
patients where the mucosal lesion was mainly induced by the
production of IFN-γ from these gluten-speciﬁc T cells. This
result suggests that transamidation neutralized the immune
reactivity of a large repertoire of epitopes. Similar results
wereobtained byusing microbialTG,whichisdiﬀerent from
tTG since it is calcium independent and is a low-molecular-
weight protein that exhibits advantages in food industrial
applications. This enzyme is commercially available as a
dough improver that adds stability and elasticity to the
dough. Additionally, bread volume and crumb texture are
positively inﬂuenced by the addition of microbial TG,
especially for ﬂours with low gluten content and poor baking
performance.
5.4. Transglutaminase Inhibitors. tTG plays an important
role in CD pathology as it catalyzes deamidation and
cross-linking of speciﬁc gluten peptides and converts them
into potent epitopes recognized by intestinal T-cells. In
order to restrain the T cell-mediated immune response to
dietary gluten, a diﬀerent approach could be to consider
tTG as a potential therapeutic target [69]. The inhibition
of the tTG-catalyzed deamidation of speciﬁc glutamine
residues within naturally digested gluten peptides might
not generate negatively charged amino acid residues and
therefore might not increase the binding to the HLA-
DQ2/DQ8 molecules (thus potentiating T cell activation).
Several inhibitors acting with diﬀerent mechanisms that
target the TG cross-linking activity have been developed and
tested, mainly in vitro [69, 70]. Among the tTG inhibitors
tested we can ﬁnd several nonspeciﬁc irreversible thiol-
reactive reagents, also named suicide TG inhibitors, such
as cystamine, able to inhibit tTG via the formation of
an enzyme-inhibitor complex. Furthermore, we can ﬁnd
competitive nonpeptidic tTG amino donor substrates, such
as 1,4-diaminobutane (Fibrostat), which is used topically
in a clinical trial to treat abnormal wound healing [71],
and competitive peptidic tTG amino donor. Finally, we can
ﬁnd amine acceptor pseudosubstrates able to inhibit tTG
activity by diverting it from the natural protein substrate.
Recently, Hoﬀmann et al. used a blocking peptide approach
to reduce the processing of gliadin by tTG. The authors
showed that these peptides have a potential for gluten
detoxiﬁcation and could be evaluated as an alternative for
designing new food products for gluten-intolerant patients
[72]. Several factors must be taken into consideration whenEnzyme Research 7
designing a tTG inhibitor: inhibitory potency, optimal size
of the compound, resistance towards intestinal proteolytic
activities (to this end, amino acid residues will be replaced
by peptidomimetics), and selectivity towards tTG. In fact,
the lack of speciﬁcity limits therapeutic utility. Furthermore,
to reduce the risk of systemic side eﬀects, the activity of an
optimal tTG inhibitor should be speciﬁcally limited to the
compartment where gliadin encounters the immune system,
that is, in the gut. Therefore, blocking the transamidating
activity of tTG represents an attractive tool to prevent
immune activation. Similar approaches have already been
investigated in other diseases where tTG is involved, such
as in the neurodegenerative disorders such as Parkinson,
Huntington, and Alzheimer diseases, as well as in cancer and
in ﬁbrotic/scarring conditions such as diabetic nephropathy.
Consequently, tTG inhibitory drugs can be predicted to have
a wide medical application.
6. Concluding Remarks
The high incidence of CD in the worldwide population is a
challenging task, given the negative impact of a strict gluten-
free diet on the perceived quality of life of celiac patients
for several reasons. A life-long gluten-free diet is not easy
to maintain since gluten is the most common ingredient
in the human diet. Multidisciplinary research eﬀorts are
currently being carried out in several directions to ﬁnd
new treatment strategies in order to reduce gluten toxicity.
The use of oral proteases capable of detoxifying ingested
gluten and new food grade fermentation technologies using
bacterial-derived endopeptidases currently represent the
most advanced and promising strategies.
Abbreviations
CD: Celiac disease
SS: Disulphide
tTG: Tissue transglutaminase
HLA: Human leukocyte antigen
IFN: Interferon
IL: Interleukin.
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